Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.16 (calcineurin)
 17,112 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seborrheic dermatitis (SD) is a chronic, recurrent, inflammatory skin disorder occurring in areas rich in sebaceous glands. It manifests clinically as erythematous macules or plaques with varying levels of scaling and associated pruritus. Although the pathogenesis of SD has yet to be fully understood, Malassezia yeasts, hormones, sebum levels, and immune response are known to play important roles. Additional factors including drugs, winter temperatures, and stress may exacerbate SD. Current available treatments include antifungal agents, topical low-potency steroids, and calcineurin inhibitors. We aimed to evaluate the effectiveness of a topical non-steroidal cream in treating facial seborrheic dermatitis (FSD). We performed a case series of 11 patients with mild or moderate FSD and a history of several previous treatments without improvement. The patients were treated for 8 weeks with a topical non-steroidal facial cream (NSFC) containing zinc PCA, piroctone olamine, hydroxyphenyl propamidobenzoic acid, biosaccharide gum-2, and stearyl glycyrrhetinate. Signs and symptoms and tolerance were assessed before, during, and at the end of treatment. All of the patients had improved symptoms of FSD (desquamation, pruritus, erythema, and stinging sensation); 81.8% showed an excellent response and 18.1% showed a good response. None of the patients had adverse effects. J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.5121.
 ...
PMID:Non-Steroidal Topical Therapy for Facial Seborrheic Dermatitis. 3257 15

Atopic dermatitis is a chronic inflammatory disease of the skin, which is characterized by itching, erythema and eczematous lacerations. It affects about 10 % of adults and approximately 15-20 % of children in the worldwide. As a result of genetic, immunologic and environmental factors, the disease manifests itself with impaired stratum corneum barrier and then immunological responses. Topical administration of corticosteroids and calcineurin inhibitors are currently used as the first strategy in the management of disease. However, they have low skin bioavailability and some side effects. The nano-carriers as novel drug delivery systems could overcome limitations of conventional dosage forms, owing to increment of poorly soluble drug' solubility, then its thermodynamic activity and consequently its skin permeation. Also, side effects of the drug substances on the skin could be reduced by the nano sized drug delivery systems, due to encapsulation of the drug in the nano-carriers and targeted drug delivery of drug substances to the inflammated skin areas. Thereby, there have been available a numerous of research studies and patents regarding use of the nano-carriers in the management of atopic dermatitis. This review focuses on the mechanism of disease and, developments on the nano-carrier based on novel drug release systems of in the management of atopic dermatitis.
 ...
PMID:Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment. 3281 64


<< Previous 1 2 3 4